Hepatocellular carcinoma (HCC) is a primary form of liver cancer that starts in liver cells, or hepatocytes. People with hepatitis B, C, cirrhosis, overweight and high blood pressure are more likely to develop the disease. Imaging techniques such as ultrasound, MRI, CT scan, and liver biopsy are used to diagnose hepatocellular cancer. Radiation therapy, ablation therapy, chemotherapy, and targeted drug therapy are the most common forms of treatment for hepatocellular cancer. The majority of patients with HCC are identified when their liver disease has progressed to the point that they can no longer function. The death rate is almost equal to the incidence rate due to the poor prognosis of the disease. As a result, early identification of cancer is an essential endpoint for improving the survival of patients with hepatocellular carcinoma, thereby contributing to the growth of the global hepatocellular carcinoma drugs market.
Get a sample report with the latest information @ https://www.coherentmarketinsights.com/insight/request-sample/1596
The increasing global prevalence of hepatocellular carcinoma patients is an important factor in the expansion of the global hepatocellular carcinoma drugs market. According to a 2014 study published in the International Journal of Cancer Research and Treatment, HCC is the sixth most common form of cancer and the third leading cause of death worldwide, with men ranking fifth and women eighth. In addition, the arrival of new health problems such as hepatitis B and C viral infections, thyroid disorders such as diabetes and non-alcoholic fatty liver disease, and exposure to toxins such as Alcohol and aflatoxin has been linked to an increase in the frequency and death rates of hepatocellular carcinoma.
Clinical improvements, along with regulatory approval of new drugs for the treatment of hepatocellular carcinoma, are driving the expansion of the global hepatocellular carcinoma drug market. Regorafenib (Stivarga), a drug manufactured by Bayer HealthCare Pharmaceuticals Inc., was approved by the United States Food and Drug Administration in April 2017 for the treatment of patients with hepatocellular carcinoma.
Adverse drug reactions such as anemia, diarrhea, low white blood cell count, and pneumonia are limiting the expansion of the global hepatocellular carcinoma drug market.
Buy this premium report here to access all the information @ https://www.coherentmarketinsights.com/insight/buy-now/1596
Due to the increased incidence of the disease and the growing number of clinical trials conducted by companies to address the unmet medical needs of patients, North America is expected to maintain a leading position in the global anti-drug market. hepatocellular carcinoma during the forecast period. According to a survey conducted by the Department of Health Sciences at the University of California at Los Angeles (UCLA), hepatocellular carcinoma (HCC) accounts for quarters of all liver cancers in the United States, with approximately 40,000 Americans affected by the disease in 2017 and more than 28,000 deaths.
Due to the increasing amount of research and development effort by companies in the region to create effective drugs, Asia-Pacific is expected to achieve considerable traction in the global hepatocellular carcinoma drugs market. In February 2017, Daiichi Sankyo, a Japanese pharmaceutical company, completed phase III research on tivantinib, which is used to treat patients with hepatocellular carcinoma who have failed previous treatments.
The manufacturers are focusing on strategic partnerships to jointly develop and commercialize immunotherapies for a wide range of malignancies. Bristol-Myers Squibb Company and Ono Pharmaceutical Co., Ltd. announced a strategic partnership agreement in 2014 to effectively integrate and commercialize numerous immunotherapies as single agents and targeted therapy with Opdivo to address the unmet medical needs of cancer patients in Japan, South Korea, and Taiwan .
Large companies that contribute to globalization hepatocellular carcinoma drugs market are Bristol-Myers Squibb Company, Merck & Co., Inc., Bayer AG, Amgen Inc., Pfizer Inc., Novartis Pharmaceuticals, Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Celgen Corporation, Johnson & Johnson and AbbVie Inc.
Get a PDF brochure with the latest information @ https://www.coherentmarketinsights.com/insight/request-pdf/1596
Coherent Market Insights is a global market intelligence and consulting organization focused on helping our plethora of clients achieve transformational growth by helping them make critical business decisions. We have our head office in India, an office at Global Financial Capital in the United States, and business consultants in the United Kingdom and Japan. Our clientele includes players from various industries in more than 150 countries around the world. We pride ourselves on serving clients of all backgrounds, from Fortune 500 companies to nonprofits and startups looking to enter the market. We excel in providing unmatched actionable market insights across various industry verticals including chemicals and materials, healthcare, food and beverage, consumer goods, packaging, semiconductors, software and services, telecommunications and automotive. We offer syndicated market intelligence reports, custom research solutions, and advisory services.
Consistent market information
1001 4th Ave, # 3200 Seattle, WA 98154, USA
Email: [email protected]
United States of America: + 1-206-701-6702
United Kingdom: + 44-020-8133-4027
Japan: + 050-5539-1737
India: + 91-848-285-0837